| 產品編號 | bs-2941R |
| 英文名稱 | TNFR1 Rabbit pAb |
| 中文名稱 | 腫瘤壞死因子受體1抗體 |
| 別 名 | TNFRSF1a; CD120a; CD120a antigen; MGC19588; p55; p55 R; p55R; p60; TBP1; TBPI; TNF R; TNF R I; TNF R1; TNF R55; TNF-R1; Soluble TNF Receptor I; Soluble TNF p55 Receptor; TNF-RI; TNFR 1; TNFR I; TNFR-I; TNFR55; TNFR60; TNFRI; TNFRSF1a; TNR1A_HUMAN; Tumor necrosis factor alpha receptor; Tumor necrosis factor binding protein 1; Tumor necrosis factor receptor 1; Tumor necrosis factor receptor type 1; Tumor necrosis factor receptor type I; Tumor necrosis factor-binding protein 1. |
 |
Specific References (6) | bs-2941R has been referenced in 6 publications.
[IF=6.551] WB ; Rat.
[IF=2.948] Gokhan Ozge. et al. Salubrinal Ameliorates Inflammation and Neovascularization via the Caspase 3/Enos Signaling in an Alkaline-Induced Rat Corneal Neovascularization Model. MED LITH. 2023 Feb;59(2):323 IHC ; Rat.
[IF=2.914] Liu L et al. Giardia duodenalis induces extrinsic pathway of apoptosis in intestinal epithelial cells through activation of TNFR1 and K63 de-ubiquitination of RIP1 in vitro. Microb Pathog
. 2020 Dec;149:104315. WB ; Human.
[IF=2.38] Abdel-Hamid, Nagwa I., Mona F. El-Azab, and Yasser M. Moustafa. "Macrolide antibiotics differentially influence human HepG2 cytotoxicity and modulate intrinsic/extrinsic apoptotic pathways in rat hepatocellular carcinoma model." Naunyn-Schmiedeberg's Archives of Pharmacology (2017): 1-17. IHC-P ; Rat.
[IF=2.16] Fukui, Shoichi, et al. "Tumor necrosis factor alpha inhibitors have no effect on a human T-lymphotropic virus type-I (HTLV-I)-infected cell line from patients with HTLV-I-associated myelopathy." BMC Immunology 18.1 (2017): 7. IF(ICC) ; Human.
[IF=1.69] Wang et al. Inhibitory effect of Zanthoxylum bungeanum seed oil on ovalbumin?induced lung inflammation in a murine model of asthma. (2016) Mol.Med.Rep. 13:4289-302 WB ; Mouse.
|
| 研究領域 | 腫瘤 心血管 細胞生物 信號轉導 干細胞 細胞凋亡 轉錄調節因子 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 克 隆 號 | |
| 交叉反應 | Human,Mouse,Rat (predicted: Rabbit,Pig,Cow,Dog,Horse) |
| 產品應用 | WB=1:500-2000,Flow-Cyt=1ug/Test
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 50 kDa |
| 檢測分子量 | |
| 細胞定位 | 細胞膜 分泌型蛋白 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human TNFR1/TNF Receptor I: 1-100/455 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產品介紹 |
Receptor for TNFSF2/TNF-alpha and homotrimeric TNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes to the induction of non-cytocidal TNF effects including anti-viral state and activation of the acid sphingomyelinase. Function: Receptor for TNFSF2/TNF-alpha and homotrimeric TNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes to the induction of non-cytocidal TNF effects including anti-viral state and activation of the acid sphingomyelinase. Subcellular Location: Cell membrane. Secreted. Post-translational modifications: The soluble form is produced from the membrane form by proteolytic processing. DISEASE: Defects in TNFRSF1A are the cause of familial hibernian fever (FHF) [MIM:142680]; also known as tumor necrosis factor receptor-associated periodic syndrome (TRAPS). FHF is a hereditary periodic fever syndrome characterized by recurrent fever, abdominal pain, localized tender skin lesions and myalgia. Reactive amyloidosis is the main complication and occurs in 25% of cases. Similarity: Contains 1 death domain. Contains 4 TNFR-Cys repeats. SWISS: P19438 Gene ID: 7132 Database links: Entrez Gene: 7132 Human Entrez Gene: 21937 Mouse Entrez Gene: 100135698 Sheep Omim: 191190 Human SwissProt: P19438 Human SwissProt: P25118 Mouse Unigene: 279594 Human Unigene: 713833 Human Unigene: 1258 Mouse Unigene: 11119 Rat |
| 產品圖片 |
Sample: Cerebrum (Rat) Lysate at 40 ug
Primary: Anti-TNFR1 (bs-2941R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 50 kD
Observed band size: 50 kD
Blank control:TM4(blue). Primary Antibody: Rabbit Anti- TNFR2 antibody(bs-2941R), Dilution: 1μg in 100 μL 1X PBS containing 0.5% BSA; Isotype Control Antibody: Rabbit IgG (orange) ,used under the same conditions. Secondary Antibody: Goat anti-rabbit IgG-PE(white blue), Dilution: 1:200 in 1 X PBS containing 0.5% BSA.
Blank control: THP-1.
Primary Antibody (green line): Rabbit Anti-TNFR1 antibody (bs-2941R)
Dilution: 1μg /10^6 cells;
Isotype Control Antibody (orange line): Rabbit IgG .
Secondary Antibody : Goat anti-rabbit IgG-FITC
Dilution: 1μg /test.
Protocol
The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 0.1% PBST for 20 min at room temperature. The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
Blank control(blue): Hep G2 Cells(fixed with 2% paraformaldehyde (10 min) and then permeabilized with ice-cold 90% methanol for 30 min on ice). Primary Antibody: Rabbit Anti-TNFR1/FITC Conjugated antibody (bs-2941R /FITC), Dilution: 1μg in 100 μL 1X PBS containing 0.5% BSA; Isotype Control Antibody: Rabbit IgG/FITC(orange) ,used under the same conditions.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
